Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has earned a consensus recommendation of “Moderate Buy” from the five research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $19.00.

Several research analysts have weighed in on the stock. William Blair assumed coverage on shares of Kyverna Therapeutics in a research note on Wednesday, August 20th. They issued an “outperform” rating on the stock. Wells Fargo & Company upped their price objective on shares of Kyverna Therapeutics from $24.00 to $27.00 and gave the company an “overweight” rating in a research note on Wednesday, October 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Kyverna Therapeutics in a report on Tuesday, October 14th. Finally, HC Wainwright lifted their price objective on shares of Kyverna Therapeutics from $5.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, August 29th.

Institutional Trading of Kyverna Therapeutics

Large investors have recently made changes to their positions in the stock. Phoenix Wealth Advisors acquired a new position in shares of Kyverna Therapeutics during the 2nd quarter valued at about $32,000. Catalyst Funds Management Pty Ltd bought a new stake in Kyverna Therapeutics during the second quarter worth approximately $37,000. Qube Research & Technologies Ltd acquired a new position in Kyverna Therapeutics during the second quarter valued at approximately $43,000. Ethic Inc. acquired a new position in Kyverna Therapeutics during the second quarter valued at approximately $56,000. Finally, Vanguard Personalized Indexing Management LLC grew its holdings in Kyverna Therapeutics by 25.2% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 19,122 shares of the company’s stock valued at $59,000 after purchasing an additional 3,847 shares during the last quarter. Institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Stock Performance

Kyverna Therapeutics stock opened at $6.67 on Friday. The firm has a market cap of $288.48 million, a PE ratio of -1.81 and a beta of 3.72. The firm’s 50 day moving average price is $5.09 and its two-hundred day moving average price is $3.62. Kyverna Therapeutics has a twelve month low of $1.78 and a twelve month high of $7.73.

Kyverna Therapeutics (NASDAQ:KYTX) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.97) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.03. Equities analysts anticipate that Kyverna Therapeutics will post -3.29 EPS for the current fiscal year.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.